COVID-19 Infusion Information for Providers

Updated December 27, 2021

Check back often for updates to this page.

Urgent Monoclonal Antibody Update

Beginning Monday, Dec. 27, 2021: Criteria for the administration of monoclonal antibody are as followed (NOTE: this more strict version of criteria are secondary to a combination of a shortage of monoclonal antibody and transition to Sotrovimab, the more effective monoclonal antibody against the COVID-19 Omicron variant)

If a patient arrives not meeting the below criteria they will be sent back to the provider to assure ongoing monitoring. We hope to be able to get the adequate supplies to broaden our criteria, but presently we are adhering to the CDC recommended approach to assure those patients who would most benefit from this therapy would have it available to them. Please encourage booster shots as these are our best defense against serious infection.

If a patient arrives for a monoclonal antibody treatment and confirmed SPO2 is <94, he or she will be referred back to the referring provider without receiving the infusion. 94% saturation is the cut-off for differentiating between moderate and severe in the NIH Guidelines for the severity of disease in COVID-19.

Criteria

Effective Jan. 12, 2022

  • Outpatient COVID positive patient (mild to moderate symptoms by the NIH criteria)
  • Mild: Symptoms such as a fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell
  • Moderate: Evidence of lower respiratory disease (shortness of breath, dyspnea, or abnormal chest imaging) and who have an oxygen saturation (SpO2) ≥ 94% on room air at sea level
  • Symptom onset within last 5 days
  • Age ≥ 18
  • Are high-risk for progressing to severe COVID-19 and/or hospitalization
  • The patient must have oxygen saturation greater than or equal to 94% on room air OR
  • If the patient is on O2, they must not have an increased oxygen requirement OR If the patient has a known baseline pulse ox of less than 94% and does not meet the criteria for home oxygen, the provider must document that in his/her note for the patient to be eligible.
  • High risk is defined as patients who meet at least one of the following criteria:
    • Aged ≥65 years
    • Obesity (BMI ≥35)
    • Chronic lung diseases (e.g., chronic obstructive pulmonary disease, moderate-to-severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension)
    • An immunocompromising condition (e.g. organ or bone marrow transplant, severe immunocompromising therapy, excluding steroids) or immunosuppressive treatment
    • Chronic liver diseases (e.g., cirrhosis, NAFLD, alcoholic liver disease, autoimmune hepatitis)
    • CKD stage 4/5 (GFR < 30) and ESRD
    • Active Tuberculosis
    • Pregnancy
    • Neurodevelopmental disorders (e.g., cerebral palsy) or other conditions that confer medical complexity (e.g., genetic or metabolic syndromes and severe congenital anomalies)
    • Medical-related technological dependence (e.g., tracheostomy, gastrostomy, or positive pressure ventilation that is not related to COVID-19)
  • Aged ≥ 40 years, and at least two of the following:
    • Diabetes
    • Cardio- (and cerebro-)vascular disease
    • CKD stage 1/2/3
    • Sickle cell disease
    • Smoking
    • Mental health disorder (e.g., mood disorders, anxiety/fear related disorders, substance use disorder, schizophrenia spectrum disorders)
    • Obesity (BMI ≥ 30)

Cost

The federal government is providing monoclonal antibody therapy at no cost to patients. However, health care providers may charge an administration fee for treatment. Medicare and many commercial insurance companies are covering all costs for patients. Check with your health plan to learn more about treatment costs.

Frequently Asked Questions

More information about monoclonal antibodies and FAQs.

    Locations

    These treatments are currently being given in six locations:

    • NMMC-Tupelo, 612 Brunson Drive, Tupelo
    • NMMC-Iuka, 1777 Curtis Drive, Iuka
    • NMMC Gilmore-Amory, 1105 Earl Frye Blvd., Amory
    • NMMC-West Point, 977 Emergency Dr., West Point
    • North Mississippi Medical Center-Hamilton, 1256 Military Street South, Hamilton, AL
    • NMMC-Eupora, 70 Medical Plaza, Eupora

    Referral Information (EPIC)

    Providers with EPIC access: Your referrals must be made in EPIC, and a therapy plan is also required.

    EPIC referral tip sheet

    SCM referral tip sheet

    Non-EPIC Referrals

    Referral Form to Fax (Tupelo)

    Referral Form to Fax (Iuka)

    Referral Form to Fax (Amory)

    Referral Form to Fax (West Point)

    Referral Form to Fax (Hamilton)

    Referral Form to Fax (Eupora)

    Non-EPIC Referrals (Pediatrics)

    Referral Form to Fax (Tupelo)

    Referral Form to Fax (Iuka)

    Referral Form to Fax (Amory)

    Referral Form to Fax (West Point)

    Referral Form to Fax (Hamilton)

    Referral phone numbers

    Tupelo: (662) 377-2430

    Iuka: (662) 423-4060

    Amory: (662) 256-6061

    West Point: (662) 494-5232, then select option 8

    Hamilton: (205) 921-6305

    Eupora: (662) 258-9244

    Resources for Providers

    Criteria and important info to print (Tupelo)

    Criteria and important info to print (Amory)

    Criteria and important info to print (Iuka)

    Criteria and important info to print (West Point)

    Criteria and important info to print (Hamilton)

    Criteria and important info to print (Eupora)

    Bebtelovimab EUA Fact Sheet for Providers

    Casirivimab/Imdevimab FDA Fact Sheet for Providers

    Bamlanivimab/Etesevimab FDA Fact Sheet for Providers

    Sotrovimab FDA Fact Sheet for Providers

    Resources for Patients

    Info sheet to print and give to patients (Tupelo)

    Info sheet to print and give patients (Amory)

    Info sheet to print and give patients (Iuka)

    Info sheet to print and give patients (West Point)

    Info sheet to print and give patients (Hamilton)

    Info sheet to print and give patients (Eupora)

    Bebtelovimab EUA Fact Sheet for Patients

    Casirivimab/Imdevimab FDA Fact Sheet for Patients

    Bamlanivimab/Etesevimab FDA Fact Sheet for Patients

    Sotrovimab FDA Fact Sheet for Patients